Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Open Text Corporation (OTEX) Price & Performance

Mesoblast LimitedTrade
Open Text CorporationTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Open Text Corporation — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Open Text Corporation trades at $23.91 (market cap $5.80B). The key difference: Open Text Corporation is far larger — about 2.6× Mesoblast Limited's market cap, and Open Text Corporation pays a 4.67% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESOOTEX
Market Cap
$2.21B$5.80B
Sector
TechnologyTechnology
52-Week High
$20.96$39.69
52-Week Low
$12.88$20.01
Enterprise Value
$2.21B$10.81B
Dividend Yield
4.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.

Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.

Open Text Corporation

Open Text Corporation (OTEX) trades at $23.95, down 3.11% over the past day. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company shows strong profitability with a 73.74% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights Q4 2026 results with cloud revenue growth and strategic investments in AI.

The investment outlook is positive given attractive valuations like a P/E of 9.29 and a consensus price target of $29.33 implying significant upside. Key risks include execution of growth initiatives and competitive pressures in the software sector. Analyst sentiment is mixed but leans cautious with a majority hold rating.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Open Text Corporation

Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.

Read more on OTEX